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More than 100,000 carotid revascularization procedures are
performed annually in the United States, primarily for
asymptomatic stenosis to improve ﬂow and provide protec-
tion from thromboembolic events to the ipsilateral hemi-
sphere. Indications for asymptomatic carotid stenosis
revascularization stem from ACAS (Asymptomatic Carotid
Atherosclerosis Study) and ACST (Asymptomatic Carotid
Surgery Trial) (1,2). In ACST, there was a reduction inSee page 2503cerebral ischemic events from 11.8% in patients treated with
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and Interventions.for 60% carotid stenosis over 5 years. Despite the beneﬁt
for revascularization of carotid stenosis of at least 60% in
ACAS and ACST, most subsequent trials have established
a higher standard for asymptomatic disease with inclusion
criteria established at 80% carotid stenosis.
The indication for carotid revascularization in asymptomatic
patients has been recently vigorously challenged because of
improvements in medical therapies now routinely available to
patients, including rigorous management of hypercho-
lesterolemia, hyperlipidemia, diabetes mellitus, antiplatelet
regimens, and aggressive blood pressure and lifestyle inter-
ventions. This has particularly come to the fore in light of
the CREST (Carotid Revascularization Endarterectomy vs.
Stenting Trial) results, where there was no signiﬁcant differ-
ence in the incidence of the composite primary endpoint of
stroke, myocardial infarction, and death between carotid
endarterectomy and stenting (3). Even though most carotid
revascularization procedures in the United States are carotid
endarterectomies, and the vast majority of those are for >60%
asymptomatic disease, plans for expansion of indications for
carotid artery stenting (CAS) for asymptomatic disease have
been essentially abandoned, despite demonstrated equipoise of
the 2 procedures in CREST.
The principal reason for resistance to wider adoption of
CAS appears to be the incidence of cerebral ischemic events
following revascularization. Again, in CREST, there were
no signiﬁcant differences in major stroke or death between
the 2 procedures, but there were clear differences between
minor stroke and myocardial infarction (3). Also worth
noting is a signiﬁcant impact on longevity with myocardial
infarction but not with minor stroke. Interestingly, access
site complications were signiﬁcantly more common with
endarterectomy than with stenting; and cranial nerve injuries
(5% after endarterectomy) did not occur with stenting. The
focus from the community of physicians treating carotid
stenosis has been directed primarily at the effectiveness of
carotid revascularization as it pertains to prevention of
periprocedural and post-procedural ischemic events.
Attempts have been made to distinguish higher-risk
asymptomatic patients most likely to beneﬁt from carotid
revascularization. These have included transcranial embolic
studies to detect high-intensity transients (asymptomatic em-
bolic events) on ipsilateral middle cerebral artery insonation,
plaque morphology on ultrasonography with hypoechoic,
lipophilic, and/or necrotic plaque centers, or on plaque mor-
phology assessment protocols on magnetic resonance (MR)
imaging (4–8). Again, all such efforts are restricted to predic-
tion and prevention of thromboembolic ischemic events to
the cerebral circulation through revascularization approaches.
Evidence suggests that chronic carotid stenosis has
a progressive effect on cognitive decline. Johnston et al. (9)
evaluated a large, population-based cohort with asymptom-
atic carotid stenosis (4,006 patients over 5 years) and noted
progressive cognitive declines in patients with severe carotid
stenosis and increased intima-media thickness. The study
reported by Huang et al. (10) in this issue of the Journal raises
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2511the very pertinent question of effects on cognition that may be
amenable to amelioration by carotid revascularization as
a direct correlate to improvement in attenuated cerebral
perfusion. There has been a steady focus on neurocognitive
effects of carotid stenosis and response to reduction in carotid
stenosis and improvement in cerebral perfusion following
revascularization. However, results have been varied and are
often contradictory. The intuitive notion that improved blood
ﬂow should enhance cognitive function has been essentially
completely omitted from the discussion as we consider CAS
for revascularization, maintaining the focus entirely on
thromboembolic disease.
Huang et al. (10) looked at 61 patients, of whom 22
had complete occlusion and 39 had severe carotid stenosis.
They performed psychometrics on these patients, including
the Mini-Mental State Examination, Alzheimer Disease
Assessment Scale–Cognitive subscale, Trail Making Test 1
and 2, and Color Trails Test. Interestingly, these were
similar in all patients. They subsequently performed cerebral
perfusion assessment using computed tomographic perfusion
imaging with acetazolamide challenge to identify patients
with marginal perfusion. Their results are quite interesting:
only those with marginal perfusion status showed improve-
ment in cognitive function following successful revasculari-
zation. To show these effects, they used 2 groups as controls,
those with marginal perfusion and failed revascularization
(only 64% of complete carotid occlusions could be reopened)
and those with no perfusion deﬁcits who underwent revas-
cularization for stenosis. They excluded 2 periprocedural
neurological complications (3.3%) from analysis.
This study provides yet another correlate to assess risk in
asymptomatic carotid stenosis. Instead of the focus remain-
ing on thromboembolic events, this report clearly provides
evidence that revascularization in patients with asymptomatic
disease selected on the basis of marginal cerebral perfusion
may provide cognitive beneﬁt. Our main criticism of this
report pertains to the absence of a baseline difference in
psychometric scores between the 2 control groups, which
would be predicted based on the assumed hypothesis that
marginal perfusion leads to cognitive decline. This may be
explained by the fact that at the 3-month follow-up, there was
an element of cognitive decline, which transpired in those who
failed revascularization, amplifying the baseline differences to
signiﬁcance. As is expected, this report also has the inherent
limitations (as the authors recognized) that this is a small study
and deserves larger cohorts and additional psychometric and
cerebral perfusion measures.
This group has previously reported a similar improvement
in cognition after revascularization of chronic internal carot-
id artery occlusions (11). In another recent report, Cheng
et al. (12) compared 17 patients with70% unilateral asymp-
tomatic stenosis with 26 healthy controls using a more
comprehensive battery of psychometric testing as well as
imaging correlates. In particular, they applied novel MR
imaging–based protocols to assess functional hemispheric
connectivity using diffusion-tensor imaging and whole-brainfractional anisotropy paradigms. Interestingly, they noted
that patients with stenosis had worse memory and visuospatial
performance. They also noted marked decreases in inter- and
intrahemispheric functional frontoparietal connectivity in
these patients. They noted an improvement in these
functions following stent-assisted revascularization. Similar
improvements have been reported by other groups as well,
testing cognitive function before and after CAS for asymp-
tomatic stenosis (13–16) and symptomatic stenosis (16,17).
Improvements in cognition have also been reported following
endarterectomy. In a study by Fearn et al. (18) that evaluated
endarterectomy in patients with marginal cerebral perfusion,
distinct improvement was noted at 8 weeks post-procedure,
but not at 5 days. Others have contiguously evaluated both
endarterectomy and stenting, and noted clear improvement in
cognition after both at 4 to 6 months post-procedure (19).
In contrast to the rosy picture portrayed by the paper being
editorialized and the additional supporting studies noted in
the preceding text, there is a distinct body of literature that has
assessed cognitive function with the aim of demonstrating the
deleterious effects of periprocedural embolic events during
carotid revascularization. Zhou et al. (20) noted that patients
with periprocedural embolic events detected on post-
procedure MR imaging were more likely to have a decline in
memory function. Similarly, Altinbas et al. (21), in an ICSS
(International Carotid Stenting Study) substudy, reported
a nonsigniﬁcant decline in cognition following CAS and
correlated it with twice more evident embolic events on post-
procedure MR imaging. Of note, only 177 of 1,713 patients
enrolled in ICSSwere enrolled in this substudy.Of these, only
140 underwent pre-procedure testing; and of those, only 120
underwent post-procedure testing. Finally, post-procedure
testing was performed 1 month post-procedure, compared
to the study under discussion by Huang et al. (10) in which it
was performed at 3 months post-stenting. Testing latency
after the procedure may have an effect on the results; for
instance,Witt et al. (22) performed a prospective randomized
study comparing CAS and carotid endarterectomy in which
patients were evaluated pre-procedure and at 1 month, and
noted no signiﬁcant differences, whereas Raabe et al. (23)
tested a similar cohort at 1 year and noted signiﬁcant
improvements in cognitive function. Others have shown that
early declines post-procedure (after both stenting and
endarterectomy) reverse into signiﬁcant improvements by 3
months and last beyond the ﬁrst year (24).
Several authors have reviewed the literature and noted
that among 22 studies evaluating cognition, 8 demonstrated
improvements, 11 had mixed results, and 3 noted declines
post-revascularization (25,26). For example, Lehrner et al.
(27) evaluated 20 patients with symptomatic and asymp-
tomatic stenosis who underwent stenting and noted no
change at 6 months for most, and signiﬁcant improvement
and signiﬁcant decline in smaller subsets (<10% each). This
contradiction in varied cognitive outcomes is not isolated to
studies evaluating stenting but also is found in the endar-
terectomy literature (28,29). Other studies have correlated
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2512this varied response to other factors. Wasser et al. (30) noted
that although there was no signiﬁcant cognitive improve-
ment following either endarterectomy or stenting in
patients <68 years, there was a decline after both procedures
in patients 68 years. However, Feliziani et al. (31) noted
no difference from baseline up to 1 year after CAS in
patients >65 years. Weber et al. (32) found that general
anesthesia was associated with greater decline in cognitive
function than local anesthesia.
The focus on inﬂuence of embolic effects on cognition is
buttressed by studies using transcranial Doppler imaging that
demonstrates thousands of embolic events during any inter-
ventional procedure, even a diagnostic angiogram, although
no clear correlate to neurological function has been consis-
tently demonstrated (33). These transcranial Doppler–
monitored embolic-occlusive effects are further compounded
by the fact that occlusion times are typically longer during
endarterectomy, whereas embolic events (34–36) and post-
procedural hypotension (37) are more common during
stenting, again without overt clinical correlates (38). Similarly,
post-procedural MR imaging studies have consistently
demonstrated a signiﬁcant incidence of post-stenting, diffu-
sion-weighted imaging–positive hits without overt neuro-
logical correlates. In a study evaluating 24 stenting and 31
endarterectomy patients,Wasser et al. (39) noted a signiﬁcant
preponderance of diffusion-weighted imaging hits in the
stented cohort and an early decline in cognitive function,
which disappeared at testing 3 months post-procedure.
Huang et al. (10) clearly identify 3 major issues reﬂected in
the brief overview in the preceding text. Firstly, cognitive
evaluation should be an important part of initial asymptom-
atic carotid disease evaluation. Secondly, repeat testing should
be performed beyond 3 months to show lasting (rather than
transient) effects post-procedure. Finally, marginal perfusion
may identify a specially vulnerable cohort that deserves early
revascularization. This is an important study that draws our
attention to the silent decline without overt neurological or
clinical events in these patients, who merit more than just
optimized medical therapy. Further, the collective and
progressive decline in cognitive abilities in this patient
cohort compounds additional age-related neurodegenerative
processes. Such cognitive attrition likely has a signiﬁcant
impact on the quality of life and functional abilities of these
patients. Of course, the beneﬁts of revascularization need to
outweigh the detrimental effects of the procedure, including
periprocedural embolic events and hypotension. It is hoped
that wider acceptance of more effective embolic protection,
such as proximal protection devices for higher (embolic) risk
patients, and improved stent design (post-procedural embolic
protection) will lead to greater attention to cognitive effects of
chronic carotid stenosis.
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